Rare diseases
Investigational molecules
Locations
172 conditions with trials, the busiest first
481 trials across Europe, recruiting first
Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
BulgariaStudy of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk
AustriaStudy of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease
AustriaStudy of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function
BulgariaStudy on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack
AustriaBulgariaStudy on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction
BelgiumStudy on Metformin's Effect in Reducing Unplanned Heart Procedures in Non-Diabetic Patients with Acute Coronary Syndrome
PolandStudy on the Effects of Ferric Carboxymaltose on Heart Health and Quality of Life in Patients with Recent Heart Attack and Iron Deficiency
PolandStudy on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History
AustriaAustriaStudy on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions
FinlandThe therapies tested most often in Cardiac disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
